HKSE - Delayed Quote HKD

CHUNLI MEDICAL (1858.HK)

10.260
+0.750
+(7.89%)
At close: 3:59:38 PM GMT+8
Loading Chart for 1858.HK
  • Previous Close 9.510
  • Open 9.520
  • Bid 10.180 x --
  • Ask 10.220 x --
  • Day's Range 9.520 - 10.360
  • 52 Week Range 6.180 - 11.660
  • Volume 2,379,000
  • Avg. Volume 1,017,314
  • Market Cap (intraday) 6.061B
  • Beta (5Y Monthly) -0.31
  • PE Ratio (TTM) 28.50
  • EPS (TTM) 0.360
  • Earnings Date Apr 30, 2025 - May 6, 2025
  • Forward Dividend & Yield 0.54 (5.69%)
  • Ex-Dividend Date Jun 30, 2025
  • 1y Target Est 11.63

Beijing Chunlizhengda Medical Instruments Co., Ltd. engages in the research and development, production, and trading of surgical implants, instruments, and related products in the People's Republic of China. The company offers implantable orthopedic medical devices, joints, spine, sports medicine, trauma and orthopedic surgical instruments. It sells its products through distributors, or on ODM and OEM bases, as well as to hospitals directly. It also exports its products. Beijing Chunlizhengda Medical Instruments Co., Ltd. was incorporated in 1998 and is headquartered in Beijing, China.

www.clzd.com

1,237

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 1858.HK

View More

Performance Overview: 1858.HK

Trailing total returns as of 5/19/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .

YTD Return

1858.HK
20.14%
HANG SENG INDEX (^HSI)
16.31%

1-Year Return

1858.HK
3.16%
HANG SENG INDEX (^HSI)
19.33%

3-Year Return

1858.HK
36.07%
HANG SENG INDEX (^HSI)
15.96%

5-Year Return

1858.HK
78.42%
HANG SENG INDEX (^HSI)
4.33%

Compare To: 1858.HK

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 1858.HK

View More

Valuation Measures

Annual
As of 5/16/2025
  • Market Cap

    5.62B

  • Enterprise Value

    3.58B

  • Trailing P/E

    26.61

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    4.13

  • Price/Book (mrq)

    1.19

  • Enterprise Value/Revenue

    4.10

  • Enterprise Value/EBITDA

    19.51

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    15.71%

  • Return on Assets (ttm)

    1.69%

  • Return on Equity (ttm)

    4.39%

  • Revenue (ttm)

    813.85M

  • Net Income Avi to Common (ttm)

    127.86M

  • Diluted EPS (ttm)

    0.360

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.8B

  • Total Debt/Equity (mrq)

    0.03%

  • Levered Free Cash Flow (ttm)

    -88.21M

Research Analysis: 1858.HK

View More

Company Insights: 1858.HK

Research Reports: 1858.HK

View More

People Also Watch